Sweden's Isconova buys Nordic Vaccine

Isconova has purchased the Danish drug delivery and adjuvants company Nordic Vaccine for over 4 million Swedish kroner, or $663,000. "The acquisition of Nordic Vaccine is in line with Isconova's strategy to take part in the ongoing market consolidation. With the acquired patents we will strengthen our commercial opportunities and patent family within iscom and Matrix-technologies," Isconova CEO Lena Söderström said in a release.

Nordic Vaccines has similar vaccine delivery technologies as Isconova's in its portfolio, as well as a needle-free patch delivery technology that is in preclinical testing. Isconova's adjuvants are used in various bovine and equine vaccines that are manufactured by Pfizer and Merck.

- check out the Isconova release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.